Schedule 13G ownership disclosure
4D Molecular Therapeutics Inc
Security class unavailable · CUSIP: 35104E100
Event date: Unavailable
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,767,717
- Percent of class
- 5.3200%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-24-000236
- Form type
- SC 13G
- Filer
- 4D Molecular Therapeutics, Inc.
- CIK
- CIK 1650648
- Filed
- Nov 04, 2024
- Reporting period
- —
- Description
- Schedule 13G beneficial ownership